C

Corvus Pharmaceuticals
D

CRVS

8.77000
USD
0.78
(9.69%)
مغلق
حجم التداول
56,198
الربح لكل سهم
-0
العائد الربحي
-
P/E
-16
حجم السوق
654,960,017
أصول ذات صلة الأخبار المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).